fluconazole and rivaroxaban

fluconazole has been researched along with rivaroxaban in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Brings, A; Burhenne, J; Czock, D; Foerster, KI; Haefeli, WE; Lehmann, ML; Weiss, J	1
Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C	1

Trials

1 trial(s) available for fluconazole and rivaroxaban

Article	Year
Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. British journal of clinical pharmacology, 2019, Volume: 85, Issue:7 Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Fluconazole; Humans; Male; Middle Aged; Models, Biological; Rivaroxaban; Young Adult	2019

Article

Year

Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.

British journal of clinical pharmacology, 2019, Volume: 85, Issue:7

Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Fluconazole; Humans; Male; Middle Aged; Models, Biological; Rivaroxaban; Young Adult

2019

Other Studies

2 other study(ies) available for fluconazole and rivaroxaban

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. The American journal of medicine, 2022, Volume: 135, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran; Fluconazole; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke	2022

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013

Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.

The American journal of medicine, 2022, Volume: 135, Issue:5

Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran; Fluconazole; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke

2022